These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37909650)

  • 1. Radiological characteristics of hepatocellular carcinoma that achieved complete response after chemoembolization with drug-eluting beads for liver transplantation planning.
    Valle LGM; Cunha MJS; Schmid BP; Falsarella PM; Rezende MB; Felga GEG; Ogawa RE; Garcia RG; Affonso BB; Nasser F; Galastri FL
    Einstein (Sao Paulo); 2023; 21():eAO0307. PubMed ID: 37909650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 5. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma.
    Galastri FL; Nasser F; Affonso BB; Valle LGM; Odísio BC; Motta-Leal Filho JM; Salvalaggio PR; Garcia RG; de Almeida MD; Baroni RH; Wolosker N
    World J Hepatol; 2020 Jan; 12(1):21-33. PubMed ID: 31984118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
    Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
    Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).
    Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y
    Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Chemoembolization Outcomes Using 70-150 µm and 100-300 µm Drug-Eluting Beads in Treating Small Hepatocellular Carcinoma: A Korean Multicenter Study.
    Lee BC; Kim GM; Park J; Chung JW; Choi JW; Chun HJ; Oh JS; Hyun DH; Yang JH
    Korean J Radiol; 2024 Aug; 25(8):715-725. PubMed ID: 39109500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinomas within the Milan criteria: predictors of histologic necrosis after drug-eluting beads transarterial chemoembolization.
    Odisio BC; Galastri F; Avritscher R; Afonso BB; Segatelli V; Felga GE; Salvalaggio PR; Ensor J; Wallace MJ; Nasser F
    Cardiovasc Intervent Radiol; 2014 Aug; 37(4):1018-26. PubMed ID: 24149832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?
    Lee SY; Ou HY; Yu CY; Huang TL; Tsang LL; Cheng YF
    Diagn Interv Radiol; 2020 May; 26(3):230-235. PubMed ID: 32352922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort.
    Sandow TA; Arndt SE; Albar AA; DeVun DA; Kirsch DS; Gimenez JM; Bohorquez HE; Gilbert PJ; Thevenot PT; Nunez KG; Galliano GA; Cohen AJ; Kay D; Gulotta PM
    Radiology; 2018 Mar; 286(3):1072-1083. PubMed ID: 29206595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Validation of Drug-Eluting Beads Transarterial Chemoembolization of Hepatocellular Carcinomas in Living Donor Liver Transplantation.
    Tong YS; Huang TL; Chen TY; Tsang LLC; Ou HY; Yu CY; Hsu HW; Xiong LW; Liao CC; Eng HL; Chen CL; Cheng YF
    Transplant Proc; 2018 Nov; 50(9):2622-2625. PubMed ID: 30401362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
    Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
    Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.